Compare Repligen Corporation Common Stock (RGEN) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs WD 40 Company — how do they compare? Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B), while WD 40 Company trades at $205.55 (market cap $2.74B). The key difference: Repligen Corporation Common Stock is far larger — about 4.1× WD 40 Company's market cap, and WD 40 Company pays a 2% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and WD 40 Company for 23 Days on average.
| RGEN | WDFC | |
|---|---|---|
Market Cap | $11.31B | $2.74B |
Volume | 1,216,919 | 123,545 |
Sector | Health | Basic Materials |
52-Week High | $194.57 | $264.91 |
52-Week Low | $102.87 | $187.52 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $11.20B | $2.80B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
WDFC trades at $204.41, up 0.8% today, with a bullish technical signal from moving averages and key resistance at $206. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.33, and maintains robust profitability with a 33.22% ROE. Recent news highlights strategic growth initiatives and institutional buying interest.
Outlook is mixed; solid fundamentals and growth strategy support upside, but high valuation (P/E 31.07) and margin pressures from input costs pose risks. Analyst consensus is cautious with 71% hold ratings, indicating tempered expectations despite operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
